(Q37852717)

24 August 2017

1 reference

title

Safety of omalizumab in asthma (English)

1 reference

24 August 2017

0 references

2

Jonathan Corren

1 reference

24 August 2017

Ricardo A Tan

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

15 March 2011

1 reference

Expert Opinion on Drug Safety

24 August 2017

published in

1 reference

24 August 2017

volume

10

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

463-471

1 reference

24 August 2017

cites work

Omalizumab for asthma.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Immunological and clinical changes in allergic asthmatics following treatment with omalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Omalizumab-induced reductions in mast cell Fce psilon RI expression and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Effect of omalizumab on patients with chronic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Effects of omalizumab in patients with food allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Baseline characteristics of patients enrolled in EXCELS: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Omalizumab is effective in the long-term control of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Safety and tolerability of omalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Efficacy and Safety of Subcutaneous Omalizumab vs Placebo as Add-on Therapy to Corticosteroids for Children and Adults With Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Cancer incidence among 78,000 asthmatic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Difficult asthma or Churg-Strauss syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Churg-Strauss vasculitis in a patient treated with omalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.563840

10.1517/14740338.2011.563840

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference